TRMT2A and breast cancer: Our data suggests that HER2+/TRMT2A+ breast cancers are more likely to recur treated with traditional cytotoxic therapy alone and therefore more aggressive treatment in the adjuvant setting may need to be considered for these patients, regardless of the other conventional risk factors.